Treatment involves colorectal cancer patients at 20 medical centers.
XBiotech announced that it has enrolled its first patient in a multi-center, randomized clinical trial of Natrunix. This treatment is analyzed in combination with trifluridine and tipiracil for the treatment of colorectal cancer.
XBiotech’s clinical research on cancer treatment candidates is funded by the French National Institute for Cancer Research (INCA).
Subjects undergoing experimental therapy have previously failed treatment with oxaliplatin, irinotecan, and fluoropyrimidines. Alternatively, participants will be randomized to receive chemotherapy with natornix and trifluridine/tipiracil or placebo and chemotherapy. The study is designed to seamlessly advance Phase 3 development, building on the achievement of specific efficacy milestones in the Phase 1 and Phase 2 portions.
Natrunix is a therapeutic monoclonal antibody discovered, manufactured and developed by XBiotech. Antibodies block the activity of substances produced by tumor and inflammatory cells that stimulate the formation of new blood vessels and destroy connective tissue at the tumor site, allowing them to grow and spread.
In addition, the same substances activate blood vessels, making them sticky and promoting the migration of circulating tumor cells to new metastatic sites. Natrunix potently blocks the action of a substance known as IL-1 that is produced in response to chemotherapy.
Colorectal cancer is one of the most common cancers in Europe and the United States, with the American Cancer Society estimating over 151,000 new cases and over 52,000 deaths annually in the United States alone.
